When was Diadexus founded?

Diadexus was founded in 1997 and raised its 1st funding round 10 years after it was founded.

Where is Diadexus located?

Diadexus is headquartered in San Francisco, United States. It is registered at 349 OYSTER POINT BOULEVARD,SOUTH SAN FRANCISCO,94080,CA.

How many employees does Diadexus have?

As of Aug 31, 2026, the latest employee count at Diadexus is 23.

Is Diadexus a funded company?

Diadexus is a funded company, having raised a total of $49.2M across 3 funding rounds to date. The company's 1st funding round was a $***** Series E round, raised on Jan 12, 2007.

When was the latest funding round of Diadexus?

Diadexus' latest funding was a $***** Conventional Debt round on Jun 08, 2010, with participation from 0 investor.

What is the annual revenue of Diadexus?

Annual revenue of Diadexus is between $10M and $50M as on Dec 31, 2015

Where does Diadexus rank among its competitors?

Diadexus ranks 7th amongst 86 active competitors, of which 24 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was SmartHealth, which secured $300K in Nov, 2024.

Who are the top competitors of Diadexus?

Diadexus' top competitors include GEN inCode, Proxim Diagnostics and SmartHealth. Among them, SmartHealth secured the most recent funding round in November, 2024.

Diadexus - 2026 Company Profile, Funding & Competitors

Diadexus is an acquired company based in San Francisco (United States), founded in 1997. It operates as an Innovating clinical diagnostics with advanced enzyme and immunoassay technologies. Diadexus has raised $49.2M in funding. The company has 86 active competitors, including 24 funded and 18 that have exited. Its top competitors include companies like GEN inCode, Proxim Diagnostics and SmartHealth.

Company Details

Innovating clinical diagnostics with advanced enzyme and immunoassay technologies. The company specializes in researching, developing, manufacturing, and distributing high-quality diagnostic reagents for automated analyzers. They focus on proprietary enzyme and immunoassay technologies to advance healthcare. Their products cover a wide range of disease areas, including cardiovascular, cancer, liver, renal, diabetes, sepsis, inflammatory diseases, vitamins, and electrolytes. They develop clinical diagnostic tests that address technically challenging or unique clinical needs. They utilize enzymatic assay and immunoassay technologies to create cost-effective and user-friendly clinical diagnostic products. They offer a range of assays, including chemiluminescent immunoassays (CLIA) and single-molecule sensitive chemiluminescent assays (SMS-CLA). They are a medical device manufacturer certified in cGMP and ISO 13485.

Website: diadexus.com
Registered Address: 349 OYSTER POINT BOULEVARD,SOUTH SAN FRANCISCO,94080,CA

Key Metrics

Founded Year

1997

Location

San Francisco, United States

Stage

Acquired

Total Funding

$49.2M in 3 rounds

Latest Funding Round

Conventional Debt, Jun 08, 2010, $*****

Investors

Brookside Capital & 5 more

Ranked

7^th among 86 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2015

Employee Count

23 as on Aug 31, 2026

Similar Companies

GEN inCode & 113 more

Exit Details

Acquired by Diazyme Laboratories (Apr 01, 2016)

View Diadexus' full profile

Diadexus is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Diadexus, Inc. CIN: 1036968 , United States, Active		$10M - $50M (As on Dec 31, 2015)	-	-

Diadexus got acquired by Diazyme Laboratories on Apr 01, 2016.

Click here to take a look at Diadexus's acquisition in detail

Diadexus has raised a total funding of $49.2M over 3 rounds. Its first funding round was on Jan 12, 2007. Diadexus has 6 institutional investors.

Here is the list of recent funding rounds of Diadexus:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 08, 2010	8012836	Conventional Debt	9035540	7965852	5512843	4381703
Feb 06, 2009	9411140	Series F	3200763	6372760	3875775	Scale Venture Partners
Jan 12, 2007	9968403	Series E	6903751	4155135	9155389	Scale Venture Partners & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Diadexus's funding rounds and investors

Diadexus' employee count trend

Diadexus has 23 employees as of Aug 26. Here is Diadexus's employee count trend over the years:

Uncover Diadexus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Diadexus include GEN inCode, Proxim Diagnostics and SmartHealth. Here is the list of Top 10 competitors of Diadexus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	GEN inCode 2018, Manchester (United Kingdom), Public	Developer of precison medicines by combining genetic and clinical data for cardiac disease monitoring	$5.46M	Downing, Maven Capital Partners & 4 others	57/100
2nd	Proxim Diagnostics 2010, Sunnyvale (United States), Series B	Developer of a handheld immunodiagnostic device for cardiac vascular diseases	$22.9M	BioMerieux, UCLA Ventures & 1 others	52/100
3rd	SmartHealth 1979, Irvine (United States), Series B	Developer precision diagnostics for vascular, metabolic, and oncological diseases	$17.3M	-	49/100
4th	Realview Imaging 2008, Yokneam Illit (Israel), Series C	Provides 3D holographic display based solutions for medical imaging applications	$25M	OurCrowd, ADIP & 10 others	49/100
5th	Zora Biosciences 2016, Espoo (Finland), Funding Raised	Provider of diagnostic solutions for cardiovascular diseases and cancer	-	Europa, Voima Ventures	46/100
6th	Epsilon Imaging 2008, Ann Arbor (United States), Series B	Advanced echo analysis software solutions improving cardiovascular care and workflow	$4.63M	ID Ventures, Michigan Angel Fund & 5 others	46/100
7th	Diadexus 1997, San Francisco (United States), Acquired	Innovating clinical diagnostics with advanced enzyme and immunoassay technologies	$49.2M	Brookside Capital, Burrill and Company & 4 others	43/100
8th	Prolight Diagnostics 2000, Lund (Sweden), Public	Provider of Point-of-Care systems for in-vitro diagnostic tests from a drop of blood	-	-	44/100
9th	Magnisense 2003, Paris (France), Series A	Develops emergency diagnostic tests for cardiovascular diseases	$11.5M	Noshaq, Concorde & 1 others	39/100
10th	Boston Heart Diagnostics 2007, Framingham (United States), Acquired	Developer of diagnosis for personalized care for cardiovascular diseases	$10.3M	Bain Capital Ventures, Silversmith Capital Partners ... & 9 others	39/100